Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Recilisib (ON 01210) is a radioprotectant,can activate AKT, PI3K activities in cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
2 mg | In stock | $ 54.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 197.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 556.00 | |
500 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 107.00 |
Description | Recilisib (ON 01210) is a radioprotectant,can activate AKT, PI3K activities in cells. |
In vitro | Recilisib Sodium increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib Sodium treatment in combination with radiation alters the MAPK signaling pathway. |
In vivo | the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice significantly increased by Recilisib Sodium. Recilisib Sodium in combination with radiation reduces CFU numbers in mice, but the Recilisib Sodium-treated mice consistently retain a capability to form differentiated colonies. Recilisib Sodium treated mice have a progenitor cell population that is never completely depleted by radiation exposure. |
Synonyms | Ex-RAD, ON 01210 |
Molecular Weight | 336.79 |
Formula | C16H13ClO4S |
CAS No. | 334969-03-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35.71 mg/mL (106.03 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Recilisib 334969-03-8 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt PI3K Phosphoinositide 3-kinase Inhibitor ON01210 Ex-RAD ON-01210 Protein kinase B PKB inhibit ON 01210 inhibitor